Cytokines and therapeutic oligonucleotides

Cytokines, Cellular and Molecular Therapy

Volumn 3, Issue 4, 1997, Pages 247-256

  Hartmann, Günther ^a   Bidlingmaier, Martin ^a   Eigler, Andreas ^a   Hacker, Ulrich ^a   Endres, Stefan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antisense; Cytokines; Molecular therapy; Therapeutic oligonucleotides

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; FOMIVIRSEN; GANCICLOVIR; INTERCELLULAR ADHESION MOLECULE 1; OBLIMERSEN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BASE PAIRING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT; RETINITIS; REVIEW; RNA BINDING; VIRUS INHIBITION;

ANIMALS; CYTOKINES; HUMANS; OLIGONUCLEOTIDES;

EID: 0030710975     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Branch AD, A hitchhikers guide to antisense and nonantisense biochemical pathways. Hepatology (1996) 24: 1517-29.
2. Jansen B, Wadl H, Inoue SA et al, Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisensc mechanism. Antisense Res Dev (1995) 5: 271-7.
3. Stein CA, Does antisense exist? Nature Med (1995) 1: 1119-21.
4. Sharma HW, Narayanan R, The therapeutic potential of antisense oligonucleotides. Bioessays (1995) 17: 1055-63.
5. Krieg AM, Yi AK, Matson S, Waldschmidt TJ et al, CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374: 546-9.
6. Chavany C, Connell Y, Neckers L, Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol (1995) 48: 738-46.
7. Obrien SG, Kirkland MA, Melo JV et al, Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia (1994) 8: 2156-62.
8. Wagner RW, Gene inhibition using antisense oligodeoxynucleotides. Nature (1994) 372: 333-5.
9. Krieg AM, Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol (1996) 4: 73-6.
10. Klinman DM, Yi AK, Beaucage SL et al, CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA (1996) 93: 2879-83.
11. Ballas ZK, Rasmussen WL, Krieg AM, Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol (1996) 157: 1840-5.
12. Cowdery JS, Chace JH, Yi AK, Krieg AM, Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides. J Immunol (1996) 156: 4570-5.
13. Halpern MD, Pisetsky DS, In vitro inhibition of murine IFNγ production by phosphorothioate deoxyguanosine oligomers. Immunopharmacology (1995) 29: 47-52.
14. Krieg AM, Matson S, Fisher E, Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev (1996) 6: 133-9.
15. Liang H, Nishioka Y, Reich CF et al, Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest (1996) 98: 1119-29.
16. Branda RF, Moore AL, Lafayette AR et al, Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J Lab Clin Med (1996) 128: 329-38.
17. Hartmann G, Krug A, Waller-Fontaine K, Endres S, Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. Mol Med (1996) 2: 429-38.
18. Taylor MF, Paulauskis JD, Weller DD, Kobzik L, In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-α mRNA. J Biol Chem (1996) 271: 17445-52.
19. Chang NS, Intrieri C, Mattison J, Armand G, Synthetic polysulfated hyaluronic acid is a potent inhibitor for tumor necrosis factor production. J Leukoc Biol (1994) 55: 778-84.
20. Hershkoviz R, Gilat D, Miron S et al, Extracellular matrix induces tumour necrosis factor-α secretion by an interaction between resting rat CD4+ T cells and macrophages. Immunology (1993) 78: 50-7.
21. Pacifici R, Basilico C, Roman J et al, Collagen-induced release of interleukin 1 from human blood mononuclear cells. Potentiation by fibronectin binding to the alpha 5 beta 1 integrin. J Clin Invest (1992) 89: 61-7.
22. Leung L, Saigo K, Grant D, Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effects of histidine-rich glycoprotein. Blood (1989) 73: 177-84.
23. Dawes J, Interactions of heparins in the vascular environment. Haemostasis (1993) 1: 212-9.
24. Stein CA, Cheng YC, Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science (1993) 261: 1004-12.
25. Schindler R, Clark BD, Dinarello CA, Dissociation between interleukin-1 β mRNA and protein synthesis in human peripheral blood mononuclear cells. J Biol Chem (1990) 265: 10 232-7.
26. Haskill S, Johnson C, Eierman D et al, Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. J Immunol (1988) 140: 1690-4.
27. Benimetskaya L, Loike JD, Khaled Z et al, Mac 1 (cd11b/cd18) is an oligodeoxynucleotide binding protein. Nature Med (1997) 3: 414-20.
28. Hartmann G, Bidlingmaier M, Jahrsdörfer B, Endres S, Playground of oligonucleotides: extrapolation from in vitro to in vivo? Nature Med (1997) 3: 702.
29. Bazzoni F, Beutler B, The tumor necrosis factor ligand and receptor families. N Engl J Med (1996) 334: 1717-25.
30. Elliott MJ, Maini RN, Feldmann M et al, Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum (1993) 36: 1681-90.
31. Elliott MJ, Maini RN, Feldmann M et al, Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344: 1105-10.
32. Elliott MJ, Maini RN, Feldmann M et al, Repeated therapy with monoclonal antibody to tumour necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344: 1125-7.
33. Stack WA, Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet (1997) 349: 521-4.
34. van Dullemen HM, van Deventer SJH, Hommes DW et al, Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109: 129-35.
35. Maini RN, Elliott MJ, Brennan FM et al, Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumathoid disease. Immunol Rev (1995) 144: 195-223.
36. Eigler A, Sinha B, Hartmann G, Endres S, Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today (1997) 18: 487-492.
37. Zucali JR, Moreb J, Use of antisense oligonucleotides to inhibit monocyte derived cytokines. In: Molecular and Cellular Biology of Cytokines (ed JJ Oppenheim, MC Powanda, MK Kluger, CA Dinarello) 315-20. Wiley-Liss, New York, 1990.
38. Witsell AL, Schook LB, Tumor necrosis factor-α is an autocrine growth regulator during macrophage differentiation. Proc Natl Acad Sci USA (1992) 89: 4754-8.
39. Abken H, Fluck J, Willecke K, Four cell-secreted cytokines act synergistically to maintain long term proliferation of human B cell lines in vitro. J Immunol (1992) 149: 2785-94.
40. Hartmann G, Krug A, Eigler A et al, Specific suppression of human tumor necrosis factor-α synthesis by antisense oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev (1996) 6: 291-9.
41. Aggarwal BB, Schwarz L, Hogan ME, Rando RF, Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. Cancer Res (1996) 56: 5156-64.
42. Lefebvre d'Hellencourt C, Diaw L, Cornillet P, Guenounou M, Inhibition of human TNF alpha and LT in cell-free extracts and in cell culture by antisense oligonucleotides. Biochim Biophys Acta (1996) 1317: 168-74.
43. Lefebvre, d'Hellencourt C, Diaw L, Guenounou M, Immunomodulation by cytokine antisense oligonucleotides. Eur Cytokine Netw (1995) 6: 7-19.
44. Yahata N, Kawai S, Higaki M, Mizushima Y, Antisense phosphorothioate oligonucleotide inhibits interleukin 1 beta production in the human macrophage-like cell line, U937. Antisense Nucleic Acid Drug Dev (1996) 6: 55-61.
45. Peng BH, Mehta NH, Fernandes K et al, Growth inhibition of malignant CD5+B (B-1) cells by antisense IL-10 oligonucleotide. Leukemia Res (1995) 19: 159-67.
46. Keller ET, Ershler WB, Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J Immunol (1995) 154: 4091-8.
47. Ncurath MF, Pettersson S, Meyer zum Büschenfelde K, Strober W, Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nature Med (1996) 2: 998-1004.
48. Autieri MV, Yue TL, Ferstein GZ, Ohlstein E, Antisense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun (1995) 213: 827-36.
49. Bennett CF, Kornbrust D, Henry S et al, An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther (1997) 280: 988-1000.
50. Helene C, Control of oncogene expression by antisense nucleic acids. Eur J Cancer (1994) 30A: 1721-6.
51. Stein CA, Tonkinson JL, Zhang LM et al, Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry (1993) 32: 4855-61.
52. Stull RA, Zon G, Szoka FCJ, Single-stranded phosphodiester and phosphorothioate oligonucleotides bind actinomycin D and interfere with tumor necrosis factor-induced lysis in the L929 cytotoxicity assay. Antisense Res Dev (1993) 3: 295-300.
53. Bennett CF, Chiang MY, Chan H, Shoemaker et al, Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol (1992) 41: 1023-33.
54. Felgner J, Bennet F, Felgner PF, Cationic lipidmediated delivery of polynucleotides. Methods: a Companion to Methods in Enzymology (1993) 5: 67-75.
55. Froehler B, Ng P, Matteucci M, Phosphoramidate analogues of DNA: synthesis and thermal stability of heteroduplexes. Nucleic Acids Res (1988) 16: 4831-9.
56. Fennewald SM, Rando RF, Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem (1995) 270: 21 718-21.
57. Weidner DA, Valdez BC, Henning D et al, Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein c23/nucleolin. FEBS Lett (1995) 366: 146-50.
58. Agrawal S, Jiang Z, Zhao Q et al, Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci USA (1997) 94: 2620-5.
59. Bradbury J, Antisense drugs move towards the clinic. Lancet (1997) 349: 259.
60. Webb A, Cunningham D, Cotter F et al, BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349: 1137-41.
61. Kisner DL, Phase development of ISIS 2922 (Fomivirsen). Presented at Nature Biotechnology Antisense 97: Targeting the Molecular Basis of Disease, Cambridge, MA, 1997.
62. Azad RF, Driver VB, Tanaka K et al, Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother (1993) 37: 1945-54.
63. Branda RF, Moore AL, Hong R et al, B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol (1996) 79: 115-21.
64. Sato Y, Roman M, Tighe H et al, Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 273: 352-4.
65. Wooldridge JE, Ballas Z, Krieg AM, Weiner G, Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood (1997) 89: 2994-8.
66. Galbraith WM, Hobson WC, Giclas PC et al, Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev (1994) 4: 201-6.